Azra Borogovac, M.D., M.S.

(877) 460-4673
Azra Borogovac, M.D., M.S.
Hematologist
Clinical Expertise
  • Hodgkin and Non-Hodgkin Lymphomas
  • Chronic Lymphocytic Leukemia
  • Hematopoietic Stem Cell Transplant
  • CAR T Cell Therapy
Research Area
  • Hematology and Hematopoietic Cell Transplantation
  • Lymphoma
Other Languages Spoken
Bosnian
Academic Appointments
  • Assistant Clinical Professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation
Clinical Teams
Hematology & Hematopoietic Cell Transplantation
Lymphoma

For Azra Borogovac, M.D., M.S., the patient is the most important part of the medical team. She sees the opportunity to provide care to people with cancer as a privilege. In her mind, there is no one-size-fits-all treatment plan. Rather, she sees each patient as a whole person with their own unique priorities and circumstances that must be considered.

Dr. Borogovac pursued her training as a physician at the University of Massachusetts Medical School, where she also trained as a resident in internal medicine. She was a fellow in hematology/oncology and stem cell transplant and cellular therapy at the University of Oklahoma Health Sciences Center, later adding an M.S. in clinical and translational science there as well. In addition, she also completed a highly competitive yearlong program at the American Society of Hematology Clinical Translational Research Institute.

A researcher seeking to improve treatment for blood cancers and ameliorate side effects, she leads clinical trials into protocols for targeted drugs, cellular therapies and blood stem cell transplants. Before joining City of Hope® in 2022, she was an assistant professor of hematology/oncology at the University of Oklahoma’s Stephenson Cancer Center.

Dr. Borogovac is fluent in Bosnian. In her free time, she likes to spend time with her daughter, hike, travel and explore new restaurants.

Location

Education & Experience

Degrees

  • 2021, M.S., Clinical and Translational Science, University of Oklahoma Health Sciences Center, Oklahoma City, OK
  • 2015, M.D., Clinical/Translational Research Pathway, University of Massachusetts Medical School, Worcester, MA

Fellowship

  • 2018–2021, Hematology/Oncology, University of Oklahoma Health Sciences Center, Oklahoma City, OK

Residency

  • 2015–2018, Internal Medicine, University of Massachusetts Medical School, Worcester, MA

Professional Experience

  • 2022–present, Assistant Clinical Professor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope Orange County Lennar Foundation Center, Irvine, CA

Publications

  • Janakiram, M., Liu, L., Goldsmith, S., Borogovac, A., Lee, S., Nathwani, N., Rosenzweig, M., Sahebi, F., & Htut, M. (2025). GPRC5D Bispecific antibody talquetamab-induced dizziness-ataxia syndrome, clinical presentation and management- a case series. Blood cancer journal, 15(1), 135. https://doi.org/10.1038/s41408-025-01342-5
  • Xiao, A., Chen, L., Pak, S., Lee, B., Mei, M., Budde, E., Siddiqi, T., Godfrey, J., Herrera, A., Kallam, A., Phillips, T., Baird, J. H., Borogovac, A., Kwak, L., Rosen, S. T., Danilov, A., Dadwal, S., Shouse, G., & Thiruvengadam, S. K. (2025). Real-world infectious complications of CD3/CD20 bispecific antibodies in relapsed/refractory non-Hodgkin lymphoma. Leukemia & lymphoma, 1–9. Advance online publication. https://doi.org/10.1080/10428194.2025.2540442
  • Woo JS, Nguyen K, Liu L, Krishnan A, Siddiqi T, Borogovac A. Mobilizing CARs: Benefits, drawbacks, and directions for outpatient CAR T-cell therapy. Semin Hematol. 2024 Oct;61(5):273-283. doi: 10.1053/j.seminhematol.2024.08.003. Epub 2024 Aug 22. PMID: 39327109.
  • Khouri J, Dima D, Li H, Hansen D, Sidana S, Shune L, Anwer F, Sborov D, Wagner C, Kocoglu MH, Atrash S, Voorhees P, Peres L, Hovanky V, Simmons G, Williams L, Raza S, Afrough A, Anderson L, Ferreri C, Hashmi H, Davis J, McGuirk J, Goldsmith S, Borogovac A, Lin Y, Midha S, Nadeem O, Locke FL, Baz R, Hamilton B, Alsina M, Sauter C, Patel K, Kaur G. Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The US Myeloma Immunotherapy Consortium Real- World Experience. Transplant Cell Ther. 2024 Jun 2:S2666-6367(24)00437-8. doi: 10.1016/j.jtct.2024.05.025. Epub ahead of print. PMID: 38834151.
  • Borogovac A, Siddiqi T. Advancing CAR T-cell therapy for chronic lymphocytic leukemia: exploring resistance mechanisms and the innovative strategies to overcome them. Cancer Drug Resist. 2024 May 14;7:18. doi: 10.20517/cdr.2023.100. PMID: 38835348; PMCID: PMC11149098.
  • Borogovac A, Siddiqi T. Transforming CLL management with immunotherapy: Investigating the potential of CAR T-cells and bispecific antibodies. Semin Hematol. 2024 Apr;61(2):119-130. doi: 10.1053/j.seminhematol.2024.01.001. Epub 2024 Jan 5. PMID: 38290860.
  • Nusrat S, Davis H, MacDougall K, George JN, Nakamura R, Borogovac A. Thrombotic Microangiopathy After Hematopoietic Stem Cell and Solid Organ Transplantation: A Review for Intensive Care Physicians. J Intensive Care Med. 2023 Nov 21:8850666231200193. doi: 10.1177/08850666231200193. PMID: 37990516.
  • Wagner CB, Boucher K, Nedved A, Micallef IN, Desai S, Hatic H, Goyal G, Zacholski E, Fegley A, Sigmund AM, Bond DA, Samuels C, Kamdar MK, Ba Aqeel S, Torka P, MacDougall K, Borogovac A, Rajeeve S, Sundaram S, Fedak K, Modi D, Travers E, Ayyappan S, Chilakamarri N, Brem EA, Ermann DA, Fitzgerald LA, Hu B, Stephens DM, Shah H. Effect of cumulative dose of brentuximab vedotin maintenance in relapsed/refractory classical Hodgkin lymphoma after autologous stem cell transplant: an analysis of real world outcomes. Haematologica. 2023 Apr 27. doi: 10.3324/haematol.2023.282780. PMID: 37102592.
  • Borogovac A, Keruakous AR, Bycko M, Holter Chakrabarti J, Ibrahimi S, Khawandanah MO, Selby GB, Yuen C, Schmidt SA, Autry MT, Al-Juhaishi T, Wieduwilt M, Asch AS. Safety and Feasibility of Outpatient Chimeric Antigen Receptor (CAR) T-Cell Therapy: Experience from a Tertiary Care Center. Bone Marrow Transplantation. 2022 Apr 11:1–3. PMID: 35411106.
  • Al-Juhaishi T, Borogovac A, Ibrahimi S, Wieduwilt M, Ahmed S. Reappraising the Role of Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed and Refractory Hodgkin’s Lymphoma: Recent Advances and Outcomes. Journal of Personalized Medicine. 2022; 12(2):125. PMID: 35207613.

View all

Ratings & Reviews

Ratings and reviews below are gathered from the Press Ganey Clinician and Group Consumer Assessment of Healthcare Providers and Systems (CG CAHPS) survey. CG CAHPS is a standardized survey that is used to measure a patient's experience in the physician office setting. Ratings are an average of all responses to questions about a provider's care, with five stars being the highest.
5.0
Show respect for what you say
4.9
Recommend this provider office
4.9
Provider explain in way you understand
4.9
Provider listen carefully to you
4.9
Spend enough time with you
4.8
Know important info medical history
4.8
Rate provider 0-10
08/11/26
Great medical service that I highly recommend. City of Hope is the best. - Verified patient
06/19/26
Great - Verified patient
06/19/26
Good - Verified patient
06/19/26
Good - Verified patient
06/12/26
The personal care, knowledge and trust coming from Dr. B could not be higher. - Verified patient